"Cholesterol, LDL" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol.
| Descriptor ID |
D008078
|
| MeSH Number(s) |
D04.210.500.247.808.197.244 D10.532.515.500 D10.570.938.208.275 D12.776.521.550.500
|
| Concept/Terms |
Cholesterol, LDL- Cholesterol, LDL
- Low Density Lipoprotein Cholesterol
- beta-Lipoprotein Cholesterol
- Cholesterol, beta-Lipoprotein
- beta Lipoprotein Cholesterol
- LDL Cholesterol
|
Below are MeSH descriptors whose meaning is more general than "Cholesterol, LDL".
Below are MeSH descriptors whose meaning is more specific than "Cholesterol, LDL".
This graph shows the total number of publications written about "Cholesterol, LDL" by people in this website by year, and whether "Cholesterol, LDL" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 2 | 2 |
| 1997 | 1 | 3 | 4 |
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 5 | 6 |
| 2000 | 1 | 4 | 5 |
| 2001 | 1 | 4 | 5 |
| 2002 | 2 | 6 | 8 |
| 2003 | 2 | 10 | 12 |
| 2004 | 1 | 8 | 9 |
| 2005 | 3 | 7 | 10 |
| 2006 | 6 | 7 | 13 |
| 2007 | 5 | 5 | 10 |
| 2008 | 7 | 4 | 11 |
| 2009 | 5 | 5 | 10 |
| 2010 | 2 | 9 | 11 |
| 2011 | 9 | 14 | 23 |
| 2012 | 3 | 14 | 17 |
| 2013 | 11 | 15 | 26 |
| 2014 | 12 | 14 | 26 |
| 2015 | 6 | 8 | 14 |
| 2016 | 10 | 14 | 24 |
| 2017 | 5 | 10 | 15 |
| 2018 | 8 | 9 | 17 |
| 2019 | 13 | 12 | 25 |
| 2020 | 5 | 8 | 13 |
| 2021 | 8 | 11 | 19 |
| 2022 | 1 | 21 | 22 |
| 2023 | 0 | 20 | 20 |
| 2024 | 4 | 10 | 14 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cholesterol, LDL" by people in Profiles.
-
Inadequate Intensification of LDL-cholesterol lowering therapy after coronary revascularization: Insights from the GOULD registry. Int J Cardiol. 2025 Feb 15; 421:132916.
-
Attainment of low-density lipoprotein cholesterol goals in patients undergoing coronary revascularization in the contemporary clinical practice. Indian Heart J. 2024 Nov-Dec; 76(6):414-417.
-
Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association. J Clin Lipidol. 2024 Sep-Oct; 18(5):e647-e663.
-
Individual Variation in the Distribution of Apolipoprotein B Levels Across the Spectrum of LDL-C or Non-HDL-C Levels. JAMA Cardiol. 2024 Aug 01; 9(8):741-747.
-
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. N Engl J Med. 2024 Sep 12; 391(10):913-925.
-
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. N Engl J Med. 2024 Sep 12; 391(10):899-912.
-
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J. 2024 08; 274:32-45.
-
It is Time to Screen for Homozygous Familial Hypercholesterolemia in the United States. Glob Heart. 2024; 19(1):43.
-
A Technology-Assisted Web Application for Consumer Access to a Nonprescription Statin Medication. J Am Coll Cardiol. 2024 May 28; 83(21):2080-2088.
-
Oral PCSK9 Inhibitors. Curr Atheroscler Rep. 2024 05; 26(5):147-152.